je.st
news
Tag: application
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
2015-08-18 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Merck Provides Additional Update: FDA Extends Action Date for Additional sBLA in Ipilimumab-Refractory Advanced Melanoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Merck is seeking approval for KEYTRUDA, at the currently approved dose of 2 mg/kg every three weeks, for the first-line treatment of unresectable or metastatic melanoma patients. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Justin Holko, 908-740-1879An Phan, 908-255-6325 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
Cybera And Verizon Simplify Business Application Delivery
2015-08-18 07:22:43| wirelessdesignonline News Articles
Franklin-based technology company, Cybera, creates solutions that help distributed enterprises connect the applications they need. With Cybera, enterprises provide their customers with a fast and convenient experience, while also keeping their networks secure.
Tags: business
application
delivery
verizon
3.103.060 Application Approval.
2015-08-14 18:11:10| PortlandOnline
Tags: application
approval
3.103.050 Application Review.
2015-08-14 18:10:40| PortlandOnline
Tags: review
application
Task Force Interest Application
2015-08-13 21:01:04| PortlandOnline
Word Document, 55kbCategory: Other Materials
Tags: interest
application
force
task
Sites : [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] next »